UPDATED: Ameridose Closed 'Out of an Abundance of Caution'
Ameridose, which has the same owners as the Framingham company linked to a meningitis outbreak, has agreed to temporarily shut down for inspection.
UPDATED, 7:05 p.m.: This story has been updated with a statement from Ameridose.
A Westborough firm that provides sterile medication in prefilled oral syringes to thousands of hospitals, has agreed to temporarily close for inspection by state and federal regulators.
The company has the same owners as the New England Compounding Center in Framingham, which produced a steroid linked to a meningitis outbreak.
Ameridose provided the following statement in an email Wednesday evening:
"Ameridose today agreed to voluntarily and temporarily cease certain operations, including production and shipping of all products, while the Massachusetts Department of Public Health, the Board of Registration in Pharmacy and the U.S. Food and Drug Administration conduct a targeted onsite inspection. This action was taken proactively and cooperatively with the Board of Registration of Pharmacy, out of an abundance of caution, to ensure the safety of all Ameridose products.
As part of this agreement, Mr. Barry Cadden has agreed to resign all corporate positions at Ameridose. Mr. Cadden has not been pharmacist in charge nor has he had any day to day role at Ameridose.
As the DPH stated earlier today, there is no indication at all of any contamination in any Ameridose products, and there has been no suggestion that medical professionals refrain from using any Ameridose products in circulation.
Ameridose voluntarily agreed to cease certain operations effective at 3 p.m. on Oct. 10, for a period ending Oct. 22. The agreement is subject to early termination or extension by mutual consent of Ameridose and the Board of Registration in Pharmacy.”